# Caligan Partners LP: Form 13F holdings

An institutional investment manager in NEW YORK, NY. SEC CIK 1727492.

- Quarter ended: 2026-06-30
- Filed: 2026-08-14
- Reported value: $2.13bn
- Positions: 28 (28 lines in the filing's table; lines for the same security and option type are added together here)
- Compared with: the 13F for the quarter ended 2026-03-31
- Filing: https://www.sec.gov/Archives/edgar/data/1727492/000142050626001809/

## Holdings

As filed, largest first. Reported value is what the manager stated at the quarter end (Jun 30, 2026), in US dollars; it is filing data, not a price. Weight is the share of the total reported value.

| Issuer | Class | Reported value | Weight | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | ---: | --- | --- |
| [LIQUIDIA CORPORATION (LQDA)](/companies/lqda.md) | COM NEW | $647.3m | 30.5% | 8,118,892 |  | Unchanged |
| [REVOLUTION MEDICINES INC (RVMD)](/companies/rvmd.md) | COM | $367.4m | 17.3% | 1,961,795 |  | Added +308,987 |
| [ABIVAX SA (ABVX)](/companies/abvx.md) | SPONSORED ADS | $207.6m | 9.8% | 1,557,924 |  | Added +96,000 |
| [VAXCYTE INC (PCVX)](/companies/pcvx.md) | COM | $127.2m | 6.0% | 2,188,636 |  | Added +127,917 |
| [EXELIXIS INC (EXEL)](/companies/exel.md) | COM | $84.5m | 4.0% | 1,553,262 |  | Unchanged |
| [TANGO THERAPEUTICS INC (TNGX)](/companies/tngx.md) | COM | $78.2m | 3.7% | 2,500,103 |  | Added +91,305 |
| [AVALO THERAPEUTICS INC (AVTX)](/companies/avtx.md) | COM NEW | $58.5m | 2.8% | 3,163,866 |  | Added +1,528,843 |
| [XENON PHARMACEUTICALS INC (XENE)](/companies/xene.md) | COM | $53.7m | 2.5% | 889,944 |  | Reduced −503,083 |
| [ADMA BIOLOGICS INC (ADMA)](/companies/adma.md) | COM | $47.9m | 2.3% | 5,725,007 |  | Added +968,496 |
| [REVOLUTION MEDICINES INC (RVMD)](/companies/rvmd.md) | COM | $47.2m | 2.2% | 251,800 | Call | Added +22,900 |
| [LB PHARMACEUTICALS INC (LBRX)](/companies/lbrx.md) | COM SHS | $46.7m | 2.2% | 1,438,070 |  | Unchanged |
| [IMMUNOCORE HLDGS PLC (IMCR)](/companies/imcr.md) | ADS | $43.9m | 2.1% | 1,381,317 |  | New +1,381,317 |
| [VIRIDIAN THERAPEUTICS INC (VRDN)](/companies/vrdn.md) | COM | $40.3m | 1.9% | 2,193,981 |  | New +2,193,981 |
| [VOR BIOPHARMA INC (VOR)](/companies/vor.md) | COM NEW | $35.4m | 1.7% | 1,925,066 |  | Unchanged |
| [SAB BIOTHERAPEUTICS INC (SABS)](/companies/sabs.md) | COM NEW | $31.1m | 1.5% | 7,967,207 |  | Unchanged |
| [INVENTIVA SA (IVA)](/companies/iva.md) | ADS | $30.9m | 1.5% | 8,163,191 |  | Added +3,188,285 |
| [AURA BIOSCIENCES INC (AURA)](/companies/aura.md) | COM | $30.5m | 1.4% | 4,298,248 |  | Added +4,068,384 |
| [TYRA BIOSCIENCES INC (TYRA)](/companies/tyra.md) | COM | $25.8m | 1.2% | 806,986 |  | Reduced −469,982 |
| [OPUS GENETICS INC (IRD)](/companies/ird.md) | COM | $25.0m | 1.2% | 6,077,084 |  | Added +2,056 |
| [ANIKA THERAPEUTICS INC (ANIK)](/companies/anik.md) | COM | $21.0m | 1.0% | 1,435,130 |  | Unchanged |
| [SAGIMET BIOSCIENCES INC (SGMT)](/companies/sgmt.md) | COM SER A | $19.3m | 0.9% | 2,500,000 |  | New +2,500,000 |
| [ARTIVA BIOTHERAPEUTICS INC (ARTV)](/companies/artv.md) | COM | $16.8m | 0.8% | 1,736,111 |  | New +1,736,111 |
| [FAETH THERAPEUTICS INC (FTH)](/companies/fth.md) | COM NEW | $15.7m | 0.7% | 629,467 |  | Added +503,465 |
| [MBX BIOSCIENCES INC (MBX)](/companies/mbx.md) | COM | $11.0m | 0.5% | 200,000 |  | Reduced −648,590 |
| [VERRICA PHARMACEUTICALS INC (VRCA)](/companies/vrca.md) | COM SHS | $5.7m | 0.3% | 923,910 |  | Unchanged |
| [AGIOS PHARMACEUTICALS INC (AGIO)](/companies/agio.md) | COM | $3.3m | 0.2% | 90,000 | Call | Unchanged |
| [ADMA BIOLOGICS INC (ADMA)](/companies/adma.md) | COM | $2.5m | 0.1% | 300,000 | Call | Unchanged |
| [CELLECTAR BIOSCIENCES INC (CLRB)](/companies/clrb.md) | COM NEW | $1.3m | <0.1% | 469,998 |  | New +469,998 |

## Sold out

Held at the end of the quarter before and not reported this quarter.

| Issuer | Class | Reported value | Weight | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | ---: | --- | --- |
| [CG ONCOLOGY INC (CGON)](/companies/cgon.md) | COM | $0 | 0.0% | 0 | Call | Sold out −900,000 |
| [MAZE THERAPEUTICS INC (MAZE)](/companies/maze.md) | COM | $0 | 0.0% | 0 |  | Sold out −614,962 |
| [MINERALYS THERAPEUTICS INC (MLYS)](/companies/mlys.md) | COM | $0 | 0.0% | 0 |  | Sold out −2,772,654 |
| [SPYRE THERAPEUTICS INC (SYRE)](/companies/syre.md) | COM NEW | $0 | 0.0% | 0 |  | Sold out −878,127 |
| [XILIO THERAPEUTICS INC (XLO)](/companies/xlo.md) | COM | $0 | 0.0% | 0 |  | Sold out −112,128 |

Source: SEC EDGAR, Form 13F-HR, accession 0001420506-26-001809. Last ingested by Listed: Oct 22, 2026, 05:26 ET. No prices; not investment advice.